

IN THE NAME OF GOD

# TOXICITY & KIDNEY INVOLVEMENT

Dr. futuhi farzaneh  
Assistant professor of nephrology  
Loghman Hakim Hospital ;SBMU



# Introduction

An overdose is a medical emergency that requires immediate medical attention

- Substances toxic to the kidney are legion in the modern world.
- Acute kidney injury (AKI) induced by poisonous or primarily nephrotoxic substances, may be community acquired with ingestion or inhalation or nosocomial.
- Many nephrotoxic plants, medications, chemicals and illicit drugs can induce AKI by varying pathophysiological pathways.
- Moreover, the epidemiology of toxic AKI varies depending on country, regions within countries, socioeconomic status and health care facilities.



In 2017, the American Association of Poison Control Centers reported more than 2.1 million human toxic exposures across the United States.

Most reported exposures were due to a few classes of prescription medications (analgesics, sedative/hypnotics, antipsychotics, antidepressants) or readily available cleaning or personal care products.


Accidental exposures are the most common among children, while suicidal ingestions are predominant among adults

In current times, according to one retrospective, case-control study using the data NPDS, of the approximate 16.8 million exposures , has reported .

There were 16 444 single substance exposures with renal effects, of which 9074 cases had serious kidney complications (55.2%).

Poisoned patients with renal impairment had higher rates of renal replacement therapy initiation (27.7%) and death (10.9%)

## EPIDEMIOLOGY



[Ren Fail.](#) 2019; 41(1): 576–594




# EPIDEMIOLOGY

- **Synthetic Opioids Including Fentanyl Helped Drive Record-High Overdose Deaths in 2020**
- [The CDC](#) data show that drug overdose deaths reached a record high of 93,331 in 2020.
- Since 2015 the percentage of all U.S. deaths attributed to overdoses has grown from 1.9 percent to 2.8 percent, even as COVID-19 increased [total deaths](#) by more than 300,000 in 2020.
- The number of Americans dying from opioid overdose remain high
- overdose deaths rose dramatically for nearly every [racial/ethnic group and age range](#).
- [Men, younger people, and Black, Latinx/Hispanic, American Indian/Alaska Native, and Asian American](#) communities reported the highest proportional increases compared to 2019.

Overdose deaths exploded to more than 90,000 in 2020, and synthetic opioids were involved in more than 60 percent of all overdose deaths.

Annual drug overdose deaths





# There are four types of poisoning:

1. **Fulminant** - Produced by a massive dose. Death occurs very rapidly, sometimes without preceding symptoms, the patient appearing to collapse suddenly.
2. **Acute** - Produced by a single dose or several small doses taken in a short period. Onset of symptoms is abrupt.
3. **Chronic** - Produced by small doses taken over a long period. Onset is insidious.
4. **Subacute** - Characterized by a mixture of features of acute and chronic poisoning.



# Causes

## Acute alcohol intoxication

- Ethyl alcohol
- Methanol poisoning
- Ethylene glycol poisoning

## • Opioid overdose

## • Sedative-hypnotics

- Barbiturate overdose
- Benzodiazepine overdose

## • Uncategorized sedative-hypnotics

- Ethchlorvynol (Placidyl)
  - GHB
  - Glutetimide (Doriden)
  - Ketamine

## • stimulants

- Cocaine overdose
- Amphetamine overdose
- Methamphetamine overdose

## • tobacco

- Nicotine poisoning

## • poly drug use

- Drug "cocktails" (speedballs)

## • Medications

- Aspirin poisoning
- Paracetamol poisoning
- Paracetamol toxicity
- Tricyclic antidepressant overdose
- Vitamin poisoning

## • Pesticide poisoning

- Organophosphate poisoning
- DDT

## • Inhalants

## • Lithium toxicity



# Clinical manifestations

The majority of poisoned patients presenting to the casualty (emergency) department are victims of acute exposure. In most cases, the poisoned patient presents with one or more of the following non-specific features:

1. Impairment of consciousness
2. Respiratory/Cardiovascular depression
3. Dehydration due to vomiting/diarrhoea
4. Hypothermia
5. Convulsions
6. Cardiac arrhythmias

**Toxic Syndromes:** Toxic syndrome or toxidrome is a constellation of toxic effects comprising a set of clinical fingerprints for a group of toxic chemicals.



# Type of toxic syndrom

## 1. Anticholinergic syndrome

*Causes:* Antihistamines, anti-parkinsonian drugs, atropine, scopolamine, amantadine, antipsychotic drugs, antidepressants, antispasmodics, skeletal muscle relaxants, many plants (especially Datura), and fungi (e.g. Amanita muscaria).

*Symptomatology:* Delirium with mumbling speech, tachycardia, dry hot skin, mydriasis, myoclonus, urinary retention, decreased bowel sounds. Convulsions and arrhythmias in severe cases.

## 2. Cholinergic syndrome

*Causes:* Organophosphates, carbamates, parasympathomimetic drugs, and some mushrooms

*Symptomatology:* Confusion, CNS depression, salivation, lacrimation, urinary and faecal incontinence, vomiting, sweating, fasciculations, seizures, miosis, pulmonary oedema, tachy/bradycardia





### **3. Sympathomimetic syndrome**

*Causes:* Cocaine, amphetamines, upper respiratory decongestants (phenylpropanolamine, ephedrine, and pseudoephedrine)

*Symptomatology:* Paranoia, delusions, tachycardia, hypertension, hyperpyrexia, sweating, mydriasis, seizures, arrhythmias

### **4. Sedative syndrome**

*Causes:* Opiates, barbiturates, benzodiazepines, ethanol, methaqualone, meprobamate, ethchlorvynol, glutethimide, clonidine

*Symptomatology:* Miosis, hypotension, bradycardia, hypothermia, CNS depression, hyporeflexia, coma, rarely convulsions.



## Common toxidromes

<i>Toxidromes</i>	<i>Mental status</i>	<i>Pupils</i>	<i>Vitals</i>	<i>Other manifestations</i>	<i>Examples of toxic agents</i>
Sympathomimetic	Hyper alert, agitation, hallucination, paranoia	Mydriasis	Hyperthermia, tachycardia, hypertension, widened pulse pressure	Diaphoresis, tremors, hyperreflexia, seizures	Cocaine, amphetamines, ephedrine, theophylline, caffeine
Anticholinergic	Agitation, hallucinations, delirium, coma	Mydriasis	Hyperthermia, tachycardia, hypertension, tachypnea	Dry flush skin, dry mucous membranes, decreased bowel sounds, urinary retention, myoclonus	Antihistamines, TCA, antiparkinsonism agents, atropine, antispasmodics
Hallucinogenic	Hallucinations, perceptual distortions, depersonalization, agitation	Mydriasis (usually)	Hyperthermia, tachycardia, hypertension, tachypnea	Nystagmus	Phencyclidine, MDMA, MDEA
Opioid	CNS depression, coma	Miosis	Bradypnea, apnea	Hyporeflexia, pulmonary edema, needle marks	Heroin, morphine, methadone, diphenoxylate
Sedative-hypnotic	CNS depression, confusion, stupor,	Variable	Often normal; hypothermia,	Hyporeflexia	Benzodiazepine, barbiturates,

# Diagnostic Evaluation

- CBC –Electrolytes-ABG
- LFTs ; BUN,CR; CXR
- ECG
- Serum lactate
- CPK LDH
- AXR
- Serum Toxin
- ASA level
- Tylenol level
- Serum OSM
- Urine Toxin [opiates, benzodiazepines, cocaine metabolites, barbiturates, tricyclic antidepressants, tetrahydrocannabinol, phencyclidine](#)
- **urinary microRNAs** can be used as early renal biomarkers following nephrotoxic-AKI (snakebite envenoming, oxalic acid, paraquat, and glyphosate poisoning)



# Immunoassay screening tests:

These assays are inexpensive and provide rapid results, usually within one hour.

Positive and negative screens for drugs do not absolutely confirm or refute poisoning diagnoses and require further evaluation.

some drugs that present in therapeutic amounts, such as opioids and benzodiazepines, may be detected by the screen even though they are causing no contributing clinical symptoms.

**Qualitative toxic** screening of urine, blood, or other body fluids (commonly by liquid and gas chromatography and mass spectrometry) is expensive can be perform , in patients with severe or unexplained toxicity





# IN METABOLIC ACIDOSIS

$$\text{Anion Gap} = \text{Na}^+ - [\text{Cl}^- + \text{HCO}_3^-] = 8 \text{ to } 12 \text{ mEq/L}$$

## • Toxins with increased AG:

- Methanol
  - Paraldehyde
  - INH
  - Fe
  - Ethylene glycol
  - Salicylates
  - CO
  - Cyanide
- Hydrogen  
Sulfide  
ETOH  
(ketones)  
Metformin  
Phenformin  
Sulfur  
Theophylline  
Toluene

## Toxins with decreased AG:

Lithium  
Bromide



# Osmolar Gap (OG)

Serum OSM:  $2[\text{Na}] + [\text{Glc}]/18 + [\text{BUN}]/2.6$

OG: Measured OSM-Calculated OSM

Normal OG: -3 to 10 mOSM/kg H<sub>2</sub>O

## Toxins with increased OG

Methanol

Ethanol

Ethylene glycol

Acetone

Isopropanol




- An increase in the osmolar gap indicates the presence of a **low molecular weight**, osmotically active substance in the serum

Normal osmolar gap does not rule out toxic alcohol intoxication because;

- (1) the patient's baseline osmolar gap is not known;
- (2) as metabolism of the parent toxic alcohol compound ensues , the osmolar gap narrows with a concomitant increase in the anion gap);
- (3) the contribution of any osmolaritically active compound to the osmolar gap related to the compound's molecular weight.

•







## **Elimination Enhancement**

Increased rate of removal of an agent to reduce mortality, complications, more invasive interventions, or LOS. In practice useful only when positive risk-benefit analysis and:

- Severe toxicity
- Poor outcome despite supportive care/antidote
- Slow endogenous rate of elimination
- Suitable pharmacokinetic properties

The various methods of eliminating absorbed poisons from the body include the following:

1. Forced Diuresis
2. Extracorporeal techniques
  - Haemodialysis
  - Haemoperfusion
  - Peritoneal dialysis
  - Haemofiltration
  - Plasmapheresis
  - Plasma perfusion
  - Cardiopulmonary bypass.



# TOXICOKINETICS & TOXICODYNAMICS


The term **toxicokinetics** denotes the absorption, distribution, excretion, and metabolism of toxins, toxic doses of therapeutic agents, and their metabolites.

The term **toxicodynamics** is used to denote the injurious effects of these substances on body functions.



# Dose-Response Relationship:

As the dose of a toxicant increases, so does the response.



DOSE DETERMINES THE BIOLOGICAL RESPONSE

The therapeutic index and the overlap of therapeutic and toxic response curves must be considered.

In the case of a drug with a linear dose-response curve (drug A), lethal effects may occur at 10 times the normal therapeutic dose.

In contrast, a drug with a curve that reaches a plateau (drug B) may not be lethal at 100 times the normal dose




# LD<sub>50</sub>

The acute lethality hazard is typically determined using the LD<sub>50</sub> which is defined as the median dose predicted to kill 50% of a given test population.

Anything with an acute oral LD<sub>50</sub> over 5 g/kg bw (or 5000 mg/kg bw) is considered to be practically nontoxic, per the Hodge-Sterner scale:


No.	Term	LD <sub>50</sub> (Rat, Oral)
1	Extremely Toxic	Less than 1 mg kg <sup>-1</sup>
2	Highly Toxic	1 - 50 mg kg <sup>-1</sup>
3	Moderately Toxic	50 - 500 mg kg <sup>-1</sup>
4	Slightly Toxic	500 - 5000 mg kg <sup>-1</sup>
5	Practically Non Toxic	5000 - 15,000 mg kg <sup>-1</sup>





# Patterns of Mortality Risk From Drugs/Substance Overdose

## A Theoretical Model



- A - High toxicity: Digoxin, tricyclic antidepressant, theophylline, carbon monoxide, cyanide
- B - Intermediate: Acetaminophen, salicylate, phenobarbital
- C - Low: Propranolol (immediate-release)
- D - Threshold for overdose effect: Atropine, phenylpropanolamine

## LD<sub>50</sub> Comparison

Chemical	LD <sub>50</sub> (mg/kg)
Ethyl Alcohol	10,000
Sodium Chloride	4,000
Ferrous Sulfate	1,500
Morphine Sulfate	900
Strychnine Sulfate	150
Nicotine	1
Black Widow	0.55
Curare	0.50
Rattle Snake	0.24
Dioxin (TCDD)	0.001
Botulinum toxin	0.0001

# FACTORS DETERMINING SEVERITY OF TOXICITY

- **Duration and concentration** of a substance at the portal of entry.
- **Rate and amount** of the substance that can be absorbed.
- **Distribution** in the body and **concentration** of the substance at specific body sites.
- **Efficiency** of biotransformation and nature of the metabolites.
- **Ability** of the substance or its metabolites **to pass through cell membranes** and come into contact with specific cell components (for example, DNA).
- **Amount and duration of storage** of the substance (or its metabolites) in body tissues.
- **Rate and sites of excretion** of the substance.
- **Age and health status** of the person exposed.



# SPECIAL ASPECTS OF TOXICOKINETICS

## ADME:

Absorption, Distribution, Metabolism, and Excretion

- **Absorption:** ability of a chemical to enter the blood
- Inhalation--readily absorb gases into the blood
- Ingestion--absorption through GI tract stomach small intestine
  - 1st Pass Effect (liver can modify)
  - Reduction in the first-pass effect can dramatically increase the absorption of oral drugs even with therapeutic doses like in patients with cirrhosis
- Drugs may injure the epithelial barrier of the gastrointestinal tract and thereby increase absorption.
- Dermal--absorption through epidermis



**Distribution of drug** the process in which a chemical agent trans locates throughout the body;  
blood flow  
characteristics of toxicant (affinity for the tissue)

## Water & lipid solubility

- Lipid soluble drugs are more penetrate rapidly into cell then water

The are directly proportional to higher lipid soluble drugs are greater rate if absorption form GIT

### *Ionization*

- Unionized drugs are lipid soluble while ionized are water soluble
- Hence, unionized drugs are better absorbed then ionized drugs in cell membrane

## Rout of administration

Parenterals routes are widely distributed the body & tissue then oral route

iv > inhale > ip > im > ingest > topical

## Protein Binding

in the case of hypoalbuminemia for highly albumin-bound substances, increases the free fraction of the drug in the blood, which increases the risk of toxicity,

The drugs with low protein binding affinity are more likely to be dialyzed,

while drugs with high protein binding affinity are more likely to be removed by plasma exchange





# Volume of Distribution

A large  $V_d$ , implies that the drug is not readily accessible to hemodialysis

The drugs with large volumes of distribution ( $> 5 \text{ L/kg}$ ) include antidepressants, antipsychotics, antimalarials, opioids, propranolol, and verapamil.

Drugs with a relatively small  $V$  ( $< 1 \text{ L/kg}$ ) include salicylate, ethanol, phenobarbital, lithium, valproic acid, and phenytoin

Poisonous substances undergoing redistribution or having a large volume of distribution may induce delayed toxicity manifestations



# Clearance

**Clearance** is a measure of the volume of plasma that is cleared of drug per unit time

The total clearance for most drugs is the sum of clearances via excretion by the kidneys and metabolism by the liver that ,important to detoxification strategy

**Overdosage of a drug can alter the usual pharmacokinetic**

If the capacity of the liver to metabolize a drug is exceeded, the first-pass effect will be reduced and more drug will be delivered to the circulation.



- **Metabolism**

- **A chemical alteration of drug form living organism is called biotransformation**


- Key organs in biotransformation

- LIVER (high)
- Lung, Kidney, Intestine (medium)
- Others (low)

- Biotransformation Pathways

- \* Phase I--make the toxicant more water soluble
- \* Phase II--Links with a soluble endogenous agent (conjugation)
- \* **If metabolites are active, as it will extend the duration of toxicity**
- \* Drug make to change first-pass effects (e.g., calcium channel blockers).

objective--make chemical agents more water soluble and easier to excrete  
decrease lipid solubility --> decrease amount at target  
increase ionization --> increase excretion rate --> decrease toxicity



# Excretion

## Two types of drug excretion

- Non- renal channel (bile, lungs ,intestine Skin ,saliva and milk)
- Renal Channel (mainly through kidney)
- Water soluble drugs mainly excreted in kidney that function are **impacted** affect of concentration.

Check first if the poison is eliminated mainly by the kidney in urine or not.  
If so, the half-life will be affected.

This will affect the decisions to utilize enhanced elimination methods, including dialysis or urine alkalinization for weak acid drugs and the observation/disposition time

- The Individualized Management Approach for Acute Poisoning",, vol. 2021



# EXTRACORPOREAL ELIMINATION

The toxins need to have a number of criteria to be effectively removed by extracorporeal elimination

low volume of distribution ( $<1.0$  L/kg),

low molecular weight ( $<5000$ Da), relatively

low protein binding

low endogenous clearance.

---

## Box 12. Toxins accessible to hemodialysis (UNSTABLE)

Uremia

No response to conventional therapy

Salicylates

Theophylline

Alcohols (isopropanol, methanol)

Boric acid, barbiturates

Lithium

Ethylene glycol

## Box 13. Enhanced elimination by charcoal hemoperfusion

Theophylline


Barbiturates

Carbamazepine

Paraquat

Glutethimide






# Substance abuse and the kidney

Metabolism and excretion of exogenously administered therapeutic agents as well as environmental exposures are other major functions of kidney.


The renal complications of drug abuse are spectrum of glomerular, interstitial and vascular diseases

• some substances are directly nephrotoxic, These effects are often chronic and irreversible, but occasionally acute with possible recovery.






# Environmental (Agro)chemical nephrotoxicity



**Abb:** ATN – acute tubular necrosis, DBCP - 1,2-dibromo-3-chloropropan, DTC - distal tubular cells,  $\text{FENa}^+$  - fractional excretion of sodium, MAC – metabolic acidosis, MM - mitochondrial membrane, NMDAR1 - *N*-methyl-D-aspartate receptor, PT - proximal tubules, PTC – proximal tubular cells, ROS – reactive oxygen species, RPP – renal perfusion pressure

## Illicit drug abuse nephrotoxicity



## REFERENCE

- ESSENTIALS OF MEDICAL PHARMACOLOGY BY K.D TRIPATHI 6<sup>TH</sup> EDITION
- BASICS AND CLINICAL PHARMACOLOGY BY KATZUNG 12<sup>TH</sup> EDITION
- PHARMACOLOGY AND PHARMACOTHERAPEUTICS BY SATOSKAR 22<sup>ND</sup> EDITION
- **GOODMAN & GILMAN'S THE PHARMACOLOGICAL BASIS OF THERAPEUTICS - 11th Ed.**



*Thank you*

